摘要
目的探讨安罗替尼联合多西他赛二线治疗驱动基因阴性晚期非小细胞肺癌(NSCLC)的临床疗效。方法依据治疗方法的不同将60例驱动基因阴性晚期NSCLC患者分为对照组(n=26)和观察组(n=34),对照组患者接受多西他赛单药治疗,观察组患者接受安罗替尼联合多西他赛治疗。比较两组患者的临床疗效、1年无进展生存情况、3级及以上不良反应发生率。结果观察组患者的总有效率和疾病控制率均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者均获得有效随访,平均随访时间为(8.26±1.06)个月。观察组患者的1年无进展生存情况优于对照组,差异有统计学意义(P﹤0.05)。两组患者的3级及以上不良反应发生率比较,差异无统计学意义(P﹥0.05)。结论与多西他赛单药相比,安罗替尼联合多西他赛二线治疗驱动基因阴性晚期NSCLC患者,可提高患者的临床疗效,改善患者的无进展生存情况,且不会明显增加不良反应。
Objective To investigate the clinical effect of anlotinib combined with docetaxel as second-line treatment for driver mutation-negative advanced non-small cell lung cancer(NSCLC).Method According to the different treatment methods,60 patients with driver mutation-negative advanced NSCLC were included in the analysis as control group(n=26)or study group(n=34).Patients in the control group were treated with docetaxel monotherapy,and those in the study group were treated with anlotinib combined with docetaxel.The clinical curative effect,1-year progression free survival(PFS)and incidence of adverse reactions of grade 3 and above were compared between the two groups.Result The overall response rate and disease control rate in study group were significantly higher than those in control group(P<0.05).Both groups were followed up effectively,with an average time of(8.26±1.06)months.The 1-year PFS in study group was significantly better than that in control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions of grade 3 or above between the two groups(P>0.05).Conclusion Compared with docetaxel monotherapy,anlotinib combined with docetaxel as second-line treatment for driver mutation-negative advanced NSCLC can improve the clinical curative effect and PFS,without increasing adverse reactions.
作者
冯继
潘娜
胡中舟
方军
FENG Ji;PAN Na;HU Zhongzhou;FANG Jun(Department of Oncology,Xinyang Central Hospital,Xinyang 464000,He’nan,China)
出处
《癌症进展》
2020年第11期1141-1143,1151,共4页
Oncology Progress
关键词
非小细胞肺癌
驱动基因阴性
晚期
安罗替尼
多西他赛
non-small cell lung cancer
drive mutation-negative
advanced
anlotinib
docetaxel
